Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
China flag China · Delayed Price · Currency is CNY
65.26
+1.75 (2.76%)
Feb 3, 2026, 3:00 PM CST

SHA:688621 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
1,0161,077930.98676.39492.86346.82
Other Revenue
1.611.611.140.210.790.54
1,0181,078932.12676.61493.65347.36
Revenue Growth (YoY)
-12.04%15.70%37.76%37.06%42.12%48.74%
Cost of Revenue
520.17537.33403.77301.15229.97175.02
Gross Profit
497.38541.14528.35375.46263.68172.33
Selling, General & Admin
159.8150.44153.24110.8185.6352.87
Research & Development
167.97171.94123.6889.6947.5834.19
Other Operating Expenses
-4.90.760.20.160.040.04
Operating Expenses
371.81364.82334.89219.32143.7290.16
Operating Income
125.57176.32193.46156.14119.9782.17
Interest Expense
-16.25-16.11-12.18-9.7-3.56-1.04
Interest & Investment Income
4.175.678.538.782.520.63
Other Non Operating Income (Expenses)
-1.09-2.66-2.47-0.96-0.720.26
EBT Excluding Unusual Items
112.39163.22187.35154.25118.2182.02
Gain (Loss) on Sale of Investments
-1.82-1.82----
Gain (Loss) on Sale of Assets
-0.56-0.31-0.71-0.25-0.51-0.08
Other Unusual Items
13.4314.96.7615.144.40.34
Pretax Income
123.44175.99193.4169.14122.182.28
Income Tax Expense
-6.056.9710.510.4313.318.12
Earnings From Continuing Operations
129.48169.01182.9158.7108.7974.16
Minority Interest in Earnings
3.528.41.86-2.23-3.13-1.7
Net Income
133.01177.41184.76156.47105.6672.46
Net Income to Common
133.01177.41184.76156.47105.6672.46
Net Income Growth
-39.92%-3.98%18.08%48.09%45.81%52.88%
Shares Outstanding (Basic)
1101121121129884
Shares Outstanding (Diluted)
1101121121129884
Shares Change (YoY)
-1.81%0.28%0.19%14.09%16.84%-0.19%
EPS (Basic)
1.211.581.651.401.080.86
EPS (Diluted)
1.211.581.651.401.080.86
EPS Growth
-38.81%-4.24%17.86%29.80%24.80%53.16%
Free Cash Flow
64.091.5419.90.093.2935.96
Free Cash Flow Per Share
0.580.010.180.000.030.43
Dividend Per Share
0.1630.1630.1650.4290.189-
Dividend Growth
-1.21%-1.21%-61.50%126.41%--
Gross Margin
48.88%50.18%56.68%55.49%53.41%49.61%
Operating Margin
12.34%16.35%20.76%23.08%24.30%23.66%
Profit Margin
13.07%16.45%19.82%23.13%21.40%20.86%
Free Cash Flow Margin
6.30%0.14%2.14%0.01%0.67%10.35%
EBITDA
153.48201.69215.47173.19131.4791.78
EBITDA Margin
15.08%18.70%23.12%25.60%26.63%26.42%
D&A For EBITDA
27.9125.3822.0117.0511.59.61
EBIT
125.57176.32193.46156.14119.9782.17
EBIT Margin
12.34%16.35%20.76%23.08%24.30%23.66%
Effective Tax Rate
-3.96%5.43%6.17%10.90%9.87%
Revenue as Reported
1,0181,078932.12676.61493.65347.36
Advertising Expenses
-0.581.691.171.130.79
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.